Skip to content

Effects of Taping & Exercise Therapy on Lower Back Musculoskeletal Conditions in Pakistani Patients

Effects of Taping & Exercise Therapy on Lower Back Musculoskeletal Conditions in Pakistani Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05649774
Enrollment
100
Registered
2022-12-14
Start date
2022-12-14
Completion date
2023-01-25
Last updated
2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lower Back Pain, Musculoskeletal Diseases or Conditions

Keywords

Lower back pain, Non specific lower back pain

Brief summary

Lower back pain has been one of the most frequently occurring musculoskeletal disorder among the females. This act as a global burden and is highly prevalent in our society. This pain can result in life long disability, loss of function and mobility among individuals. The female of the society suffers from lower back pain the most because of the under lying causes, prolong standing and stooping as well as because of hormonal changes in their bodies

Detailed description

After studying the prevalence of the lower back pain among the females of Pakistan, the investogator find the need to assess the type of their pain and find out the best way to ease their pains. The motive was to develop a treatment protocol whose effects last longer and is inexpensive for the management of lower back pain. Moreover, the investigator decided to study that which treatment protocol is better when compared to another and what is the role of sham treatment when given to the patients.

Interventions

PROCEDURETherapy

Only Myofascial Release will be provided

Only Kinesiotaping will be provided

PROCEDURETherapy with taping

Myofascial release will be provided followed by Kinesiotaping

PROCEDURESHAM

Placebo Treatment will be given

Sponsors

University of Karachi
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Intervention model description

The study was a parallel group, four arm superiority trial with 1:1 allocation ratio and balanced randomization

Eligibility

Sex/Gender
FEMALE
Age
28 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Females who were willing to participate. * Participants with nonspecific lower back pain will only be included and screened through the screening questionnaire.

Exclusion criteria

* Post-menopausal women * Females with any diagnosed co-morbidity. * Back pain progressive to any neurological deficit * Sustained or increased back pain with loss of appetite and unexplained weight loss accompanied with fever, nausea and chills * With any known spinal or lower back pathology * Tumor of the spine * Any underlying diseases of spinal cord (i.e, ankylosing spondylosis, spondolisthesis) * With any steroid therapy for lower back pain in the past three months * Any inflammatory rheumatic disease * Sensitive skin or any skin allergy or dermatological condition * Any rehabilitative services taken for the lower back pain in the past two months * Rejection to manual conatct

Design outcomes

Primary

MeasureTime frameDescription
Lower Back PainChange from baseline to week 3Numeric Pain Rating Scale
Disability of lower backChange from baseline to week 3Oswestry Disability Index

Secondary

MeasureTime frameDescription
Range of MotionChange from baseline to week 3Flexion, Extension and Lateral Bending (L and R)
Pain Pressure ThresholdChange from baseline to week 3Algometer was used to check the pain pressure threshold of Thoraco lumbar fascia, Gluteus Medius, Gluteus Maximus and Tensor Fascia Latae
Tissue HardnessChange from baseline to week 3Algometer was used to check the tissue hardness of Thoraco lumbar fascia, Gluteus Medius, Gluteus Maximus and Tensor Fascia Latae
Quality of Life of patients with Lower back painChange from baseline to week 336-Item Short Form Health Survey (SF-36)

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026